Agenus Inc. , a leader in immuno-oncology, today announced two upcoming presentations at the American Association for Cancer Research (AACR) Annual Meeting, taking place April 25?30, 2025 in Chicago, ...

Technological advancements over the past few decades have unraveled the diversity and adaptability of tumors, shedding light ...

While radiotherapy is a highly effective cancer treatment — useful for about 60 per cent of all cancers — it may lead to ...

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...

General transcription factor IIIC subunit 2 (GTF3C2) is one of the polymerase III transcription-related factors. Previous studies have revealed that ...

Discover how statin use in chronic liver disease lowers liver cancer and decompensation risks, with added benefits from ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Despite appearing successful on scans, radiotherapy may leave behind undetected microscopic cancer cells, posing a greater risk of recurrence and worse long-term outcomes than previously thought, ...

"Residual cancer is identified on histology in 40% of lung, 57–69% of renal cell, 7.7–47.6% of prostate and 0–86.7% of hepatocellular carcinoma." ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

In a US retrospective study of data on veterans with compensated cirrhosis, more than half progressed to complications after approximately 5 years.